Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.

This publication reports the SERENA-3 presurgical window-of-opportunity trial evaluating the oral SERD camizestrant in p...

Continue ReadingPharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2 breast cancer: TBCRC049 phase 2 study results.

Phase 2, single‑arm, multicenter study of tucatinib–trastuzumab–capecitabine in HER2‑positive breast cancer with...

Continue ReadingTucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2 breast cancer: TBCRC049 phase 2 study results.

Improving anti-CTLA-4 therapies through peptide masking and fragment crystallizable non‑fucosylation: preclinical characterization of three novel antibodies.

This study reports the preclinical and early clinical characterization of three next-generation anti–CTLA-4 antibodies...

Continue ReadingImproving anti-CTLA-4 therapies through peptide masking and fragment crystallizable non‑fucosylation: preclinical characterization of three novel antibodies.